BGI and H3 Biomedicine to Sequence Pre-Clinical Cancer Models
publication date: Mar 22, 2013
BGI-Shenzhen and H3 Biomedicine of Cambridge, MA have agreed to develop genomic sequencing data from pre-clinical cancer models. The research is designed to identify and validate recurrent gene mutations that are potential targets for drug therapies. BGI and H3 will share their findings with the global research community after the data analysis is completed. Earlier this week, ChinaBio® Today
published an interview with Jun Wang, PhD, the CEO of
BGI. Dr. Wang declared that pure science was always the motivating force behind the company’s alliances. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.